Stephens Consulting’s Pacira BioSciences PCRX Stock Holding History

Stephens Consulting’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-49	Closed	-$1.4K	–	616
2024 Q2	$1.4K	Buy	+49	New	+$1.4K	﹤0.01%	554

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Stephens Consulting's PCRX Position: Q3 2024 in Review

Stephens Consulting sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 49 shares — an estimated $1.4K sold.

Stephens Consulting first reported a position in PCRX in Q2 2024 and held it in 1 quarter. The position peaked at $1.4K in Q2 2024. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

Stephens Consulting reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
Stephens Consulting sold 49 Pacira BioSciences shares in Q3 2024, an estimated $1.4K.
Stephens Consulting first reported a position in Pacira BioSciences in Q2 2024 and held it in 1 quarter.
Stephens Consulting's Pacira BioSciences position peaked at $1.4K in Q2 2024.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Stephens Consulting's 13F filing for Q3 2024, filed 18 Oct 2024.